Search for clinical trials at Penn Medicine
Reversing Blindness with New FDA Approved Retinal Gene Therapy
Talk recorded by CureTalks on June 12, 2018 at 1 pm ET
In December 2017, the FDA approved the first ever DNA-altering gene therapy that can reverse an inherited form of progressive blindness. The gene therapy, called Luxturna, was developed by Jean Bennett, MD, PhD, and Albert M. Maguire, MD, spouses and co-directors of the Center for Advanced Retinal and Ocular Therapeutics at Penn Medicine.
In the following interview, the couple discusses the 25 years of work that went into the therapy and how the treatment is able to improve lost vision.
Beating Leukemia with Groundbreaking CAR-T Cell Therapy
Talk recorded by CureTalks on April 25, 2018 at 3 pm ET
Listen to Stephan Grupp, MD, discuss CAR-T cell therapy, an immunotherapy treatment that uses a patient's own genetically altered immune cells to fight cancer.
Dr. Grupp was part of the team that treated the first child, Emily Whitehead, with CAR-T cell therapy. Emily had end-stage leukemia and is now more than five years cancer free. Her father, Tom Whitehead, also discusses CAR-T and his family's experience during the chat.
Dr. Carl June's CAR-T Cell Journey and the Cancer Treatment Revolution
Talk recorded by CureTalks on November 15, 2017 at 1 pm ET
FDA approval of the breakthrough CAR-T cell therapy for cancer brings the first approved gene therapy treatment to the United States. It reprograms the body's own immune system to recognize and kill cancer cells.
Carl June, MD, is one of the pioneers of CAR-T cell research and leads the Penn Medicine team responsible for the historic FDA approval. Listen to Dr. June discuss the nuances of the treatment and what the future may hold for cancer patients.
How Will New Imaging Techniques and Genomic Tests Help In Diagnosis and Management of Prostate Cancer?
Talk recorded by CureTalks on February 9, 2016 at 6 pm ET
In this CureTalks interview, David Lee, MD, FACS, Chief of Urology at Penn Medicine, talks about recent advances in prostate cancer that have led to the discovery of new imaging and genomic tests. These tests and techniques can help patients make more informed decisions regarding their prostate cancer diagnosis, treatments and management options.